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Abstract: Pathological cardiac hypertrophy is characterized by an abnormal increase in cardiac
muscle mass in the left ventricle, resulting in cardiac dysfunction. Although various therapeutic
approaches are being continuously developed for heart failure, several studies have suggested
natural compounds as novel potential strategies. Considering relevant compounds, we investigated
a new role for Pterosin B for which the potential life-affecting biological and therapeutic effects
on cardiomyocyte hypertrophy are not fully known. Thus, we investigated whether Pterosin
B can regulate cardiomyocyte hypertrophy induced by angiotensin II (Ang II) using H9c2 cells.
The antihypertrophic effect of Pterosin B was evaluated, and the results showed that it reduced
hypertrophy-related gene expression, cell size, and protein synthesis. In addition, upon Ang II
stimulation, Pterosin B attenuated the activation and expression of major receptors, Ang II type 1
receptor and a receptor for advanced glycation end products, by inhibiting the phosphorylation
of PKC-ERK-NF-κB pathway signaling molecules. In addition, Pterosin B showed the ability to
reduce excessive intracellular reactive oxygen species, critical mediators for cardiac hypertrophy
upon Ang II exposure, by regulating the expression levels of NAD(P)H oxidase 2/4. Our results
demonstrate the protective role of Pterosin B in cardiomyocyte hypertrophy, suggesting it is a potential
therapeutic candidate.
Keywords: cardiomyocyte hypertrophy; Pterosin B; angiotensin II
1. Introduction
Pathological cardiac hypertrophy is characterized by the thickening of cardiac muscle, which leads
to irreversible morphological and functional changes and is mainly observed in patients with end-stage
heart disease. The pathological hypertrophic heart is closely associated with the development
of heart failure, arrhythmias, cerebrovascular disease, sudden death, etc [1]. Pressure overload,
such as hypertension, is one of the major causes of pathological cardiac hypertrophy, in which
angiotensin II (Ang II) has been reported to play a pivotal role [2,3]. Ang II, a vasoconstrictor
peptide of the renin-angiotensin system (RAS), plays an important role in the regulation of blood
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pressure homeostasis [4]. Under pathological circumstances, Ang II has been extensively shown to
be closely related to cardiac remodeling, such as myocardial hypertrophy and vascular hypertrophy,
which mainly acts through Ang II type 1 receptor (AT1R) in the human and animal cardiovascular
system [5–7]. AT1R activated by Ang II binding can activate various intracellular protein kinases,
such as mitogen-activated protein kinase (MAPK) family proteins, protein kinase C (PKC), and protein
kinase B (Akt) [8] and produce reactive oxygen species (ROS) via NAD(P)H oxidase (NOX) activation,
which at high levels, leads to the activation of downstream signaling pathways that can stimulate cardiac
hypertrophy, fibrosis, apoptosis, etc. [9]. In these Ang II-induced signaling pathways, activation of
nuclear factor-κB (NF-κB) as a key transcriptional factor for inflammatory mediators is critical for
the pathology of hypertension and its associated complications, such as cardiac hypertrophy [10].
Our previous data revealed that AT1R activation can stimulate receptors for advanced glycation
end products (RAGE) via extracellular secretion of high-mobility group box 1 (HMGB1), in which
HMGB1 binds the cytosolic domain of RAGE, leading to the activation of RAGE-mediated signaling
in cardiomyocyte hypertrophy [11]. In addition to RAGE, it has been recently reported that Ang II
stimulation is involved with Toll-like receptor 2 (TLR2)- and TLR4-dependent pathways in cardiac
fibrosis, hypertrophy, and dysfunction [12–15]. Moreover, HMGB1 is known to bind TLR2 and TLR4,
which recruit MyD88 to activate MAPK and NF-κB [16,17].
Bracken fern, Pteridium aquilinum, as one of the oldest and most abundant plants on Earth,
has been consumed as food by many cultures, especially in East Asia [18]. To date, many reports
have revealed the mainly toxic, carcinogenic, and cytotoxic effects of brackens, especially those related
to ptaquiloside [19,20]. However, various beneficial effects of brackens have also been reported,
including their ability to stabilize blood pressure and their immunomodulatory, anti-inflammatory,
and antioxidant effects [21–25], which are due to brackens having various beneficial components,
such as proteins, carbohydrates, fat, vitamins, carotenoids, etc. Among these beneficial components,
Pterosin B, a secondary metabolite of P. aquilinum and known as a final product of ptaquiloside,
was recently identified by its biological function; namely, Pterosin B prevents chondrocyte hypertrophy
by inhibiting Sik3 [26]. However, the potential biological and therapeutic roles of Pterosin B on
life-sustaining functions are not clear. Moreover, the effects of Pterosin B on heart disease have never
been studied. Thus, we investigated whether Pterosin B can regulate cardiomyocyte hypertrophy
induced by Ang II in vitro.
2. Results
2.1. Anti-Hypertrophic Effect of Pterosin B on Ang II-Treated Cardiomyocytes
Ang II is known as one of the major factors inducing cardiac hypertrophy [6]. Thus, we induced
cardiomyocyte hypertrophy by treatment with 300 nM Ang II using H9c2 cells, an embryonic rat
heart-derived cell line [11]. As Pterosin B has rarely been studied in hypertrophic cells, we wondered
whether it has an effect on cardiomyocyte hypertrophy. First, we measured the viability and cytotoxicity
of cell induced by Ang II with or without Pterosin B (10–100 µM) treatment. The results showed that a
300 nM Ang II treatment did not affect cell viability (Figure 1A) or cytotoxicity (Figure 1B). Pterosin B at
concentrations as high as 50 µM had no effects on Ang II-treated cells, but cell viability was decreased
by approximately 30% in 100 µM Pterosin B-treated cells. However, no significant differences in
induced cytotoxicity were detected with concentrations as high as 100 µM. Considering these results,
we treated cells with concentrations of Pterosin B up to 50 µM to investigate its anti-hypertrophic
effect. We then analyzed hypertrophy-related genes, namely, ANP, BNP, and NFATc1, in Ang II-treated
cells treated with or without Pterosin B (Figure 2A). The mRNA expression levels of ANP and BNP
increased approximately 1.5-fold upon 300 nM Ang II stimulation, and these increases were attenuated
by Pterosin B treatment in a dose-dependent manner (Figure 2B,C). The expression of NFATc1 was
increased approximately 2.5-fold, and it was also decreased by Pterosin B treatment (Figure 2D).
Although Pterosin B showed a tendency to decrease all three hypertrophy-related genes, 50 µM
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Pterosin B administered after Ang II treatment had a particularly strong effect, significantly reducing
all three genes. Therefore, we used 50 µM Pterosin B for further experiments to confirm its effects on
cardiomyocyte hypertrophy. As the most representative characteristic of myocardial hypertrophy,
the size of myocardial cells was measured through immunofluorescence staining (Figure 2E). The results
showed that the cell surface area of the cardiomyocytes was increased by approximately 250% by
Ang II, and the surface area of the cells in the Pterosin B-treated group was maintained at the level of
the control cells (Figure 2F). Additionally, there was no significant change in cell surface area in the
group treated with Pterosin B alone. Then, we analyzed the synthesis of new intracellular proteins,
which is one of the characteristics of cardiomyocyte hypertrophy (Figure 2G). As a result of visualizing
the newly synthesized protein through fluorescence staining, we confirmed that the synthesis of new
protein was inhibited in the Pterosin B treatment group. Considering these results, we suggest that
Pterosin B can affect Ang II-induced cardiomyocyte hypertrophy.
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Figure 1. Effects of Pterosin B on H9c2 cell viability. (A) Cell viability was measured by WST assay,
and (B) cytotoxicity was measured by LDH assay. Cell viability (CCK) and cytotoxicity (LDH) were
measured after treatment with 0–100 µM Pterosin B for 48 h in the presence of Ang II. Quantitative
data were expressed as the mean ± SEM of three independent experiments. *** p < 0.001.
2.2. Pterosin B Attenuates AT1R-Mediated HMGB1 Secr tio in Ang II-Induced Hy ertrophic Cardiomyocytes
It has been reported that AT1R-mediated signaling pathways are mainly involved in Ang II-induced
hypertrophic effects in the heart [27,28]. In addition, we previously demonstrated the importance of the
AT1R-HMGB1–RAGE axis in Ang II-induced cardiomyocyte hypertrophy [11]. Therefore, we examined
the protein expression levels of AT1R and RAGE in Ang II-treated cardiomyocytes by immunoblot
analysis (Figure 3A). The protein expression levels of AT1R and RAGE in the Ang II-treated cells were
increased approximately 1.5-fold compared to those of the control, showing that Pterosin B significantly
attenuated these receptors (Figure 3B,C). Next, we determined the protein level of intracellular HMGB1
in Ang II-treated cell lysates and the amount of secreted HMGB1 in Ang II-treated culture medium
(Figure 3D). The protein levels of HMGB1 were increased in the Ang II-treated cell lysates and culture
media. The expression and secretion of HMGB1 were decreased in the Pterosin B-treated cells compared
with the Ang II-treated cells (Figure 3E,F). In parallel, we investigated the protein levels of TLR2
and TLR4, which are activated by HMGB1 [17], in Ang II-induced hypertrophic cardiomyocytes.
The results showed that the expression levels of TLR2 and TLR4 were increased approximately 1.5-fold
in the Ang II-treated cells (Figure 3F), and the levels of TLR2 and TLR4 were decreased in the Pterosin
B-treated cells. In particular, both TLR2 and TLR4 showed a tendency to respond to Ang II and
Pterosin B, but only the effect on TLR2 was significant (Figure 3G,H). In addition, we examined the
protein expression of MyD88, which is a as a downstream adaptor protein critical for the TLR signaling
pathway [29], and the results showed that MyD88 expression was also increased by Ang II treatment
and was subsequently reduced by Pterosin B treatment (Figure 3F,I). These results suggested that
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Pterosin B may regulate the AT1R-HMGB1-RAGE axis as well as the TLR2-MyD88 pathway in Ang
II-treated cardiomyocytes.Molecules 2019, 24, x FOR PEER REVIEW 4 of 15 
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Figure 2. Anti-hypertrophic Effect of Pterosin B on Ang II-stimulated H9c2 cells. H9c2 cells were
treated with 10–50 µM Pterosin B for 48 h in the presence of 300 nM ANG II. (A) Expression levels
of cardiomyocyte hypertrophy-related mRNAs (ANP, BNP, and NF Tc1) were estimated by reverse
transcriptase PCR. (B–D) The ANP, BNP, and NFATc1 mRNA expression levels were normalized by
GAPDH. * < 0.05, ** p < 0.01. n = 3. (E) Texas-Red X-tagged phalloidin wa stained for F-actin in
H9c2 cells. Representative image was d tected by confocal microscopy. P50 = Pterosin B (50 µM).
Scale bar = 50 µm. (F) Average cell size was measured in each group and analyzed by Image J software.
** p < 0.01. n = 6. (G) Protein synthesis of H9c2 cells was determined using Click-iT® HPG Alexa
Fluor® 488 Protein Synthesis Assay Kit. Green fluorescence indicates synthesis of new intracellular
proteins and blue fluorescence (DAPI) indicates nucleus. P50 = Pterosin B (50 µM). Scale bar = 100 µm.
(H) Quantification of the fluorescence intensity of protein synthesis. ** p < 0.01, *** p < 0.001. Scale bar
= 100 µm. n = 4.
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Figure 3. Effects of Pterosin B on Ang II-activated HMGB1 secretion. H9c2 cells were treated with
300 nM Ang II with o without Pterosin B. (A) Protein expression levels of AT1R and RAGE in H9c2
cells-treated with 300 nM Ang II with or without Ptero in B for 48 h. (B,C) Quantification of AT1R
and RAGE expression levels shown in (A). The pr tein levels were normalized to GAPDH. * p < 0.05,
** p < 0.01, *** p < 0.001. n = 6. D H9c2 cells w r treated with Ang II for 10 min and HMGB1
expression level was detected by Western blot from cell lysate and culture edium. (E) Quantification of
intracellular HMGB1 protein levels and amount of secr ted HMGB1 shown in (D). * p < 0.05, ** p < 0.01,
*** p < 0.001. NS vs. control. n = 4. (F) H9c2 cells were treated with Ang II with or without Pterosin B
for 48 h. Western blot was performed to detect protein expression levels of TLR2, TLR4, and MyD88.
(G–I) Quantification of protein levels shown in (F). * p < 0.05, *** p < 0.001. 2 (n = 6), TLR4 (n = 6),
and MyD88 (n = 3).
2.3. Pterosin B Attenuates Ang II-Mediated Signaling Pathways
Next, we investigated the effect of Pterosin B on the AT1R downstream signaling pathway in
Ang II-induced cardiomyocyte hypertrophy. The results showed that Ang II increased the PKC
phosphorylation by approximately 1.7-fold compared to the level of the control group. The level
of phospho-PKC was decreased and maintained at the control level in Pterosin B-treated cells.
In addition, the increased levels of phosphorylated ERK in the Ang II-treated cells were decreased
in the Pterosin B-treated cells (Figure 4A,B). We further investigated the phosphorylation of NF-κB,
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a major transcription factor in myocardial hypertrophy. The phosphorylation level of NF-κB was
increased approximately 1.5-fold in the Ang II-treated cardiomyocytes, whereas Pterosin B reduced the
phosphorylation level of NF-κB to a level similar to that of the control group (Figure 4C,D). These results
suggested that Pterosin B can modulate myocardial hypertrophy by regulating the PKC-ERK-NF-κB
signaling pathway in Ang II-stimulated hypertrophic cardiomyocytes.
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Figure 4. Pterosin B attenuates PKC-ERK activation in Ang II-induced cardiomyocyte hypertrophy.
(A) H9c2 cells were treated with 300 nM Ang II for 10 min with or without Pterosin B and protein levels
were analyzed by western blotting. (B) The values of the relative p-PKC (n = 6) and p-ERK (n = 7) were
normalized by PKC and ERK, respectively. * p < 0.05, ** p < 0.01, *** p < 0.001. (C) H9c2 cells were
treated ith 300 nM Ang II for 2 h in the presence and absence of Pterosin B, and protein levels of
NF-κB and p-NF-κB were examined by western blotting. (D) Quantification of protein levels shown in
(C). * p < 0.05. n = 3.
2.4. Pterosin B Attenuates Ang II-Induced Intracellular ROS
In the cardiovascular system, the AT1R-NOX axis generates cytosolic ROS upon Ang II stimulation,
and these ROS ac ivate various hypertrophic signa ing factors, such as MAP kinase and NF-kB [30–32].
Therefore, we investigated whether Pterosin B can control cytosolic ROS production in Ang II-stimulated
cardiomyocytes. The cells treated with Ang II with or without Pterosin B were incubated with the
ROS indicator H2DCFDA, and intracellular ROS levels were assessed through confocal microscopy
(Figure 5A). The cytosolic ROS level of Pterosin B-pretreated cells after Ang II stimulation for 2 h was
maintained to a level similar to that of the control group, although the cytosolic ROS level was increased
by approximately 15% in the Ang II-treated cardiomyocytes (Figure 5A,B). In addition, the expression
levels of NOX2 and NOX4, which are the major isoforms in cardiomyocytes [33], were evaluated by
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immunoblotting (Figure 5C). The expression levels of NOX2 and NOX4 were increased in the Ang
II-induced cardiomyocytes by approximately 35% and 30%, respectively (Figure 5D,E). The expression
of NOX2 and NOX4 was significantly decreased in the Pterosin B-treated cells. Based on these results,
we suggest that Pterosin B regulates intracellular ROS levels by regulating NOX2 and NOX4 expression.
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Figure 5. Anti-oxidant effect of Pterosin B in Ang II-treated H9c2 cells. (A) H9c2 cells were treated
with 300 nM Ang II for 2 h with or without Pterosin B. The intracellular ROS levels were detected
by CM-H2DCFDA (upper panel) and phase-contrast image was obtained to confirm cell morphology
(lower panel). P50 = Pterosin B (50 µM). Scale bar = 100 µm. (B) Quantification of the fluorescence
intensity of H9c2 cells in each condition. n = 6. (C) H9c2 cells were treated with 300 nM Ang II with or
without Pterosin B for 2 h and the protein expression of NOX2, NOX4, and GAPDH was examined
by western blotting. (D–E) Quantification of protein levels shown in (C). The levels of protein were
normalized to GAPDH expression. * p < 0.05, ** p < 0.01. n = 3.
3. Discussion
Our data showed that Pterosin B attenuates AT1R-mediated signaling pathways upon Ang
II-stimulation of hypertrophic cardiomyocytes, in which Pterosin B inhibits the increase in cytosolic
HMGB1 protein levels and secretio into the extracellular nvironme t that leads to the activation of
RAGE nd its downstream signaling. It has been suggested that Ang II increases th protein levels of
RAGE, TLR2, TLR4, HMGB1, and even AT1R itself through NF-κB activation, resulting in a p sitive
feedback loop [34,35]. In these experiments, Pterosin B blocked the positive feedback loop by inhibiting
PKC- RK-NF-κB activation. An in vitro assay suggested that Pterosin B (50–500 µM) may not be able
to bind RAGE directly (Figure S1). We also confirmed that Pterosin B suppresses Ang II-induced
excessive production of ROS, which are critical mediators of signaling pathways that lead to cardiac
hypertrophy (Figure 6). It has been reported that ROS production is mediated through PKC and NOX
activation upon Ang II stimulation. Similar to our findings on NOX expression levels, various studies
have supported the association of NOX activity and expression levels with ROS production. Dai et al.
emphasized the roles of NOX2 and NOX4 to produce intracellular ROS by Ang II-stimulated AT1R,
depending on their intracellular location [36,37]. Zhang et al. demonstrated that NOX 4 expression
levels also affect ROS production through the use of silencing and overexpression experiments [38],
and using an overexpression in vivo model, Dai et al. also evaluated the regulatory effects of NOX2
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expression levels on vascular remodeling and hypertension [39]. However, additional validation such
as NADH Oxidase activity is needed to elucidate the ability of Pterosin B against intracellular ROS.
In addition, a recent study revealed a new role for ROS, showing that, under hypoxic conditions and
ultraviolet radiation, they can induce the secretion of HMGB1 from the nucleus into the extracellular
area [40,41].
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Considering the findi gs from our study, we suggest that extracellular HMGB1, as a downstream
signal of AT1R stimulation, is one of the major mediators of RAGE activation. A ubiquitous nuclear
protein, HMGB1 cts as a damage-associated molecular pattern (DAMP) upon passive or active
secretion f om damag d or stressed cells [42]. Various studies have shown the critical roles of
extra ellular HMGB1 in ardiovascular diseases, including myocarditis and car iomyopathies [43,44].
Ou previous studies also showed that an anti-HMGB1 antibody attenu ted RAGE expression and its
dow stream effector NF-κB activation in Ang II-induced ndothelial dysfuncti and cardiomyocyte
hypertrophy [11,34]. Although the mechanism of extracellular HMGB1 secretion upon Ang II-i duced
cardiomyocyte hypertrophy is p orly understood, Oh et al. demonstrated that classical PKC, not ERK
or NF-κB, can p osphorylate HMGB1, resulting in extracellular HMGB1 secretion from LPS-stimulated
Raw264.7 cells, and An et al. showed PKC-induced phosphorylation and secretio of HMGB1 using
a bone can r pain model [45,46]. Regarding HMGB1 secretio in an Ang II-induced environment,
Zhou et al. recently provided another novel mechanism, in which Ang II can induce HMGB1 elease
by increasing the hyperacetylation of HMGB1, by separation from a complex of HMGB1 and SIRT1
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in Raw264.7 cells [47]. To address the possible mechanisms controlling HMGB1 release in Ang
II-induced cardiomyocyte hypertrophy, we need further experiments using a PKC inhibitor or an
anti-SIRT1 antibody.
Finally, we further assessed hERG assay to predict the possible use of Pterosin B as a pharmaceutical
compound. Pterosin B at 50 µM showed the hERG inhibition by approximately 6.7% (Figure S2). As a
cardiac repolarizing potassium channel, the hERG channel has been reported to be associated with
long QT syndrome due to unintended blocking [48]. As diverse chemicals can bind and block the
hERG channel, several agents, such as terfenadine and astemizole, have been withdrawn from the
market because of the potential occurrence of sudden cardiac death [49,50]. Therefore, further study
using the new synthesis of Pterosin B derivatives is necessary to overcome this safety issue.
4. Materials and Methods
4.1. Reagent
The Pterosin B was purchased from Santa Cruz Biotechnology (catalog number: sc-476730, Dallas,
TX, USA) and dissolved in DMSO before use.
4.2. Induction of Cardiomyocyte Hypertrophy In Vitro
H9c2 cells (Korean Cell Line Bank, Seoul, Korea) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplied with 10%
Fetal Bovine Serum (FBS; Atlas Biologicals, Fort Collins, CO, USA) and 1% Penicillin-Streptomycin
(P/S; Gibo, Thermo Fisher Scientific, Waltham, MA, USA) at 37 ◦C under humidified conditions (5% CO2
atmosphere). The cells were cultured for 24 h in DMEM supplied with 0.5% FBS to expose the cells to
starvation. To induce hypertrophy, 300 nM Ang II is treated in the cells for 48 h then, the hypertrophy
was examined.
4.3. Cell Viability/Cytotoxicity Assay
For analyze the cell viability / cytotoxicity, 5 × 103 cells per well were seeded in 96-well plates
and incubated for 24 h at 37 ◦C under humidified conditions (5% CO2 atmosphere). Then, cells were
incubated for 24 h in a DMEM containing 0.5% FBS. The cells were treated with Pterosin B at
concentrations of 10, 25, and 50 µM for 1 h, and Ang II was then treated for 48 h.
4.3.1. Cell Viability
Then, EZ-Cytox Kit (DoGen, Seoul, Korea) is an assay kit based on water soluble tetrazolium salt
(WST) assay. The assay reagent was added to each well at final concentration of 0.5 mg/mL and the
cells were incubated for 2 h at 37 ◦C under humidified conditions (5% CO2 atmosphere). To check cell
viability, the absorbance was measured at 450 nm by a microplate reader (Thermo Fisher Scientific,
Waltham, MA, USA).
4.3.2. Cytotoxicity Assay
The experiment was conducted using Lactate dehydrogenase (LDH) Cytotoxicity Detection Kit
(Takara Bio Inc, Kusatsu, Japan), according to a manufacturer’s protocol. Briefly, the Pterosin B-treated
cells were incubated for 48 h then and 100 µL of cell-culture supernatant was transferred into optically
clear 96-well flat bottom microtiter plate. To determine the LDH activity, 100 µL of reaction mixture
was added and incubated for 30 min at room temperature. The absorbance at 490 nm was measured
using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). The absorbance value of
assay medium as background control was subtracted from other values of test samples.
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4.4. Immunocytochemistry and Cardiomyocyte Cell Size Measurement
2× 104 cells per well were seeded in 4-well chamber slide and induced cardiomyocyte hypertrophy
by Ang II treatment. 48 h after the incubation, the cells were fixed with 4% paraformaldehyde for
10 min at room temperature, it was then washed twice with PBS and was permeabilized with 0.2%
Triton X-100 for 10 min. Next, it was washed with PBS, was blocked with blocking solution (1% bovine
serum albumin) for 1 h, and then was stained with Texas Red™-X Phalloidin (Thermo Fisher Scientific,
Waltham, MA, USA). Immunofluorescence was detected by confocal microscopy (LSM 700; Carl Zeiss,
Wetzlar, Germany). More than 50 cells in 10 randomly selected regions per experiment were measured
in six independent experiments. The cell size was measured using ImageJ software, version 1.48v
(National Institutes of Health, Bethesda, MD, USA).
4.5. Reverse Transcription PCR Analysis
The level of each gene transcript was quantified using polymerase chain reaction (PCR). Total RNA
was extracted from a 60 mm culture dish using Hybrid-R (Total RNA isolation kit; GeneAll, Seoul, Korea)
according to the manufacturer’s instructions then, cDNA synthesis was performed using a Maxime™
RT Premix kit (iNtRON Biotechnology, Seongnam, Korea). The EmeraldAmp® GT PCR Master Mix
(Takara Bio Inc, Kusatsu, Japan) was used to perform PCR. The level of each gene transcript was
normalized to GAPDH. PCR primers are listed as follows: ANP forward primer: 5′- TGA GCC GAG
ACA GCA AAC-3′; ANP reverse primer: 5′-CTC ATC TTC TAC CGG CAT CTT C-3′; BNP forward
primer: 5′-TCT GCT CCT GCT TTT CCT TA-3′; BNP reverse primer: 5′-GAA CTA TGT GCC ATC TTG
GA -3′; NFATC1 forward primer: 5′-TCC ACG ATG TGG AGG TGG AAG ACG-3′; NFATC1 reverse
primer: 5′-TGA TGG CTG CCA CAA TAG CAG AGC-3′; GAPDH forward primer: 5′-GGT CTT GCT
GTG GAC TGG AT-3′; GAPDH reverse primer: 5′-CTG CTA CAG CAA ATG GGT GA-3′.
4.6. Quantification of Protein Synthesis
To measure protein synthesis, we used Click-iT™ HPG Alexa Fluor™ 594 Protein Synthesis
Assay Kit (Thermo Fisher, Waltham, MA, USA). Cells were incubated in L-methionine-free DMEM
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) for 30 min prior to the addition of 50 µM
methionine analog L-homopropargylglycine (HPG) for 30 min. After fixation and permeabilization,
the Click-iT reaction using Alexa-488 was performed according to the manufacture’s protocol.
Immunofluorescence was detected via confocal microscopy (LSM700; Carl Zeiss, Jena, Germany) Then,
immune-fluorescence intensities were measured and analyzed using Zen software (Carl Zeiss, Jena,
Germany), in which around 5–10 randomly selected regions per experiment were measured in three
independent experiments and fluorescence intensities of each group were normalized by number of
4′,6-diamidino-2-phenylindole (DAPI)-positive cells.
4.7. Immunoblot Analysis
Cells were washed once with PBS and lysed in RIPA buffer (Thermo Scientific Inc. Waltham, MA,
USA). Protein concentration was measured using a bovine serum albumin standard (Thermo Scientific Inc.
Waltham, MA, USA). The proteins were then separated in a 10% sodium dodecyl sulfate-polyacrylamide
gel and transferred to a polyvinylidene difluoride membrane (EMD Millipore, Burlington, MA, USA).
After blocking the membrane using 10% nonfat dried milk diluted with Tris-buffered saline-Tween
20 (TBS-T, 0.1%) for 1 h at room temperature, the membrane was shortly washed with TBS-T twice
and incubated with the primary antibody overnight at 4 ◦C. The following antibodies were used in
these experiments: anti-MEK1/2 (#9122, Cell Signaling, Danvers, MA, USA), anti-phospho-MEK1/2
(#9121, Cell Signaling), anti-ERK1/2 (#9102, Cell Signaling), anti-phospho-ERK1/2 (#9101, Cell Signaling),
anti-phospho-PKC (#9371, Cell Signaling), anti-PKC (#610127, Cell Signaling), anti-phoshpo-NFkB (#6956S,
Cell Signaling), anti-NFkB (#3033S, Cell Signaling), anti-AT1R (#AAR-011, Alommone Labs, Jerusalem,
Israel), anti-RAGE (#ab225533, Abcam, Cambridge, UK), anti-TLR2 (#ab213676, Abcam, Cambridge, UK),
Molecules 2020, 25, 5279 11 of 14
anti-TLR4 (#NB100-56566, Novus, Centennial, CO, USA), anti-Myod88 (#LS-C384717-100, LSBio, Seattle,
WA, USA), anti-NOX2 (#ab129068, Abcam, Cambridge, UK), anti-NOX4 (#ab109225, Abcam, Cambridge,
UK), and anti-β-actin (A5316, Sigma Aldrich, St. Louis, MO, USA). The membrane was rinsed three
times with 0.1% TBS-T for 5 min then, was incubated with peroxidase-conjugated secondary antibodies
(Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h at RT. After the membrane was rinsed six times for 5
min each, the bands were detected with the AmershamECL Prime Western Blotting Detection Reagent
(GE Healthcare, Little Chalfont, UK). The band intensities were obtained by a Davinch-Western imaging
system (Davinch K, Seoul, Korea) and were analyzed using ImageJ software, version 1.48v (National
Institutes of Health, Bethesda, MD, USA).
4.8. Measuring Cytosolic ROS Levels
Cytosolic ROS level was measured in 300 nM Ang II with or without treatment of 50 µM Pterosin B
treated cells. The cells were plated in 24-well plates. Next day, 50µM Pterosin B was treated for 1 h followed
by 2 h treatment of 300 nM Ang II. Next, the cells were washed with PBS twice, and were resuspended in
pre-warmed PBS containing 10 µM CM-H2DCFDA dye (C6827, Thermo Fisher Scientific, Waltham, MA,
USA) for ROS detection. The cells were then incubated at 37 ◦C for 10 min to render the dye responsive to
oxidation. Fluorescence images were obtained from 6 independent experiments (10–15 randomly selected
regions per each experiment). Fluorescence intensities were measured using CELL IMAGING CELENA®
X high content imaging system (CX 30000, Logos Biosystems, Anyang, Korea).
4.9. Statistical Analysis
The data was expressed as the mean ± SEM. The significance of differences between two groups
was compared using Student’s t-test. Comparisons of more than two groups were performed via
one-way ANOVA with Bonferroni correction. P values were indicated in figure legends.
5. Conclusions
In the present study, we investigated the effects of Pterosin B on Ang II-induced cardiomyocyte
hypertrophy, in which Pterosin B attenuated activation of major hypertrophic signaling pathways and
also can regulate excessive cytosolic ROS production in the presence of Ang II. However, additional in
depth study to elucidate the underlying mechanisms in details and to validate its therapeutic efficacy
using in vitro and in vivo models.
Supplementary Materials: The following are available online at, Figure S1: Binding ability of Pterosin B on
RAGE, Figure S2: The effect of Pterosin B on cardiac ion channel current.
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